Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABUS 
Arbutus Biopharma Corp (ABUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/11/2025: ABUS (3-star) is a STRONG-BUY. BUY since 67 days. Simulated Profits (38.53%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.17
1 Year Target Price $5.17
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.89% | Avg. Invested days 45 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 879.90M USD | Price to earnings Ratio - | 1Y Target Price 5.17 |
Price to earnings Ratio - | 1Y Target Price 5.17 | ||
Volume (30-day avg) 4 | Beta 0.65 | 52 Weeks Range 2.71 - 5.10 | Updated Date 11/11/2025 |
52 Weeks Range 2.71 - 5.10 | Updated Date 11/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.0325 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 17.81% |
Management Effectiveness
Return on Assets (TTM) -21.01% | Return on Equity (TTM) -52.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 782898010 | Price to Sales(TTM) 57.08 |
Enterprise Value 782898010 | Price to Sales(TTM) 57.08 | ||
Enterprise Value to Revenue 50.78 | Enterprise Value to EBITDA -5.64 | Shares Outstanding 191698695 | Shares Floating 126049560 |
Shares Outstanding 191698695 | Shares Floating 126049560 | ||
Percent Insiders 21.87 | Percent Institutions 62.5 |
Upturn AI SWOT
Arbutus Biopharma Corp
Company Overview
History and Background
Arbutus Biopharma Corp. (ABUS) was founded in 2007, initially as Tekmira Pharmaceuticals. It focuses on developing novel therapeutics for chronic hepatitis B virus (HBV) infection. Key milestones include the development of lipid nanoparticle (LNP) delivery technology and advancing HBV-targeting drug candidates through clinical trials.
Core Business Areas
- HBV Therapeutics Development: Arbutus is focused on developing a functional cure for chronic HBV infection. This includes multiple approaches such as RNA interference, capsid inhibitors, and PD-L1 inhibitors.
Leadership and Structure
William Collier is the President and CEO. The company has a board of directors and various management teams responsible for research, clinical development, and operations.
Top Products and Market Share
Key Offerings
- AB-729 (RNAi therapeutic): AB-729 is an RNAi therapeutic designed to reduce hepatitis B surface antigen (HBsAg) levels. It's currently in clinical development. Market share data is not yet applicable as it is not yet commercially available. Competitors include companies developing similar RNAi or other HBV therapeutics, such as GSK and Roche.
- AB-101 (PD-L1 inhibitor): AB-101 is a PD-L1 inhibitor designed to promote HBV-specific immune responses. It's currently in clinical development. Market share data is not yet applicable as it is not yet commercially available. Competitors include companies developing similar PD-L1 or other HBV therapeutics, such as Bristol Myers Squibb and Merck.
Market Dynamics
Industry Overview
The HBV therapeutics market is large and growing, driven by the high prevalence of chronic HBV infection globally. There is a significant unmet need for functional cures.
Positioning
Arbutus is positioned as a leader in developing novel HBV therapeutics, particularly focusing on RNAi and other innovative approaches to achieve functional cures. Their competitive advantage lies in their expertise and intellectual property in these areas.
Total Addressable Market (TAM)
The global HBV therapeutics market is projected to reach billions of dollars. Arbutus is positioned to capture a significant share of this market if its therapies are successful.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced management team
- Promising pipeline of HBV therapeutics
- Proprietary LNP technology
Weaknesses
- Dependence on clinical trial success
- Limited revenue stream currently
- High cash burn rate
- Susceptible to clinical trial failures
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Acquisition by a larger company
Threats
- Competition from other HBV therapeutics developers
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- Gilead (GILD)
- Roche (RHHBY)
- GSK (GSK)
Competitive Landscape
Arbutus faces intense competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its innovative RNAi and LNP technologies.
Growth Trajectory and Initiatives
Historical Growth: Arbutus has grown its pipeline and advanced its HBV programs through clinical trials.
Future Projections: Future growth depends on clinical trial success and potential partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing AB-729 and AB-101 through clinical trials and exploring new therapeutic approaches for HBV.
Summary
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing a cure for HBV. The company's strengths lie in its innovative technologies and experienced team, but it faces challenges related to clinical trial success and financial sustainability. Positive clinical data and strategic partnerships are crucial for future growth, which it must achieve to compete with larger players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Clinicaltrials.gov
- Arbutus Biopharma Corp. website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arbutus Biopharma Corp
Exchange NASDAQ | Headquaters Warminster, PA, United States | ||
IPO Launch date 2015-08-03 | President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.arbutusbio.com |
Full time employees 44 | Website https://www.arbutusbio.com | ||
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.